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PARKINSON’S disease (PD) is an extra-pyramidal neu-
rodegenerative disorder, in which alterations of the
immune system are involved. Interleukin (IL)-15
stimulates cellular immune response and induces
growth and differentiation of various immune cells.
RANTES, promoting leukocyte infiltration to sites of
inflammation, mediates the trafficking and homing
of immune cells. To clarify the potential effect of
levodopa on the immunological network of PD, we
analyzed IL-15 and RANTES serum levels in PD
patients, treated or not with levodopa, and in healthy
donors. Levodopa-treated patients showed signifi-
cantly higher IL-15 and RANTES circulating levels
with respect to healthy controls and higher, although
not significantly, levels with respect to untreated
patients. So, we hypothesize that the immunological
alterations found in PD may be linked, at least in part,
to levodopa therapy.
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Parkinson’s disease (PD) is an extra-pyramidal neu-
rodegenerative disorder characterized by a decreased
number of nigrostriatal dopaminergic neurons, in
which alterations of the immune system have been
postulated to be one of the mechanisms underlying
the pathogenesis.
1 In particular, alteration of cytokine
production, such as interleukin (IL)-6, by brain and
peripheral blood cells in PD patients was found.
2
IL-15, a monocyte and epithelial cell-derived
cytokine, produced in response to environmental
stimuli and infectious agents, shares a variety of
biological functions including stimulation and main-
tenance of the cellular immune response.
3 This
cytokine, similar to IL-2 in receptor specificity and
biological functions (the specificity for IL-15 is
provided by unique private a-chain receptors), is
important for the growth and differentiation of B
lymophocytes and T lymphocytes, natural killer cells
cells, macrophages and monocytes; and, conse-
quently, its pleiotropic activity results in immunor-
egulatory cross-talk between natural and specific
immune cells.
3
RANTES, a pro-inflammatory chemokine, is a small
protein of 68 amino acids that induces leukocyte
migration and mediates the trafficking and homing of
classical lymphoid cells such as T cells and mono-
cytes, but also acts on a range of other cells, including
basophils, eosinophils, natural killer cells, dendritic
cells and mast cells
4 RANTES acts by promoting
leukocyte infiltration to sites of inflammation.
4
Since, at present, there are no data regarding IL-15
and RANTES serum levels in parkinsonian patients, in
order to clarify the role of these mediators and the
effect of levodopa in the pathogenesis of PD we
analyzed IL-15 and RANTES serum levels in untreated
and in levodopa-treated PD patients, comparing the
results with a group of healthy donors.
Twenty-four patients affected by idiopathic PD, in
accordance with Gelb criteria, were consecutively
recruited: 12 patients (eight male, four female)
received l-dopamine therapy (group A) and 12
patients (seven male, five female) were free from
any specific anti-parkinsonian treatment (group B).
In group A the mean age was 65.15 years (range, 54/
75 years), the mean l-dopamine dosage was 6759 /
180 mg/day, the mean Hoehn and Yahr stage was
3.19 /0.5, and the mean duration of illness was 849 /23
months. In group B, the mean age was 58.4 years
(range, 45/77 years), mean Hoehn and Yahr stage
was 1.39 /0.2, and the mean duration of illness was
269 /10 months. Twelve healthy donors (group C),
sex and age matched, were enrolled as controls.
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consent.
A 10 ml blood sample was collected from the
antecubital vein, allowed to clot at room temperature
for 2 h, separated by centrifugation at 200 x g for 15
min in a 4235 A centrifuge (ALC Int. S.r.L., Milan,
Italy) and stored at /808C until use.
Serum IL-15 and RANTES levels were assayed by
immunoenzymatic methods (Quantikine Human IL-
15 and Human RANTES ELISA kits; R&D System,
SPACE Import/Export, Milan, Italy). The minimum
detectable dose of IL-15 and RANTES is B/2 pg/ml
and 8 pg/ml, respectively.
Differences in serum levels were assessed by one-
way analysis of variance and the Student/Newman/
Keults test. Data were expressed as the mean9 /
standard deviation. p B/0.05 was considered signifi-
cant.
Correlation coefficients were calculated with the
Spearman rank test. All data were analyzed using
the STAT VIEW SE program (Abacus, Berkeley, CA,
USA).
This preliminary study shows normal values of
circulating IL-15 and RANTES in untreated PD
patients, confirming a different involvement of the
various mediators in the ambit of PD (Fig. 1A,B).
For example, Bessler et al. showed that the
production of IL-2 by peripheral blood mononuclear
cells (PBMC) from PD patients was significantly lower
with respect to healthy controls, whereas the secre-
tion of IL-1b, IL-6 and TNF-a was significantly
enhanced.
1
FIG. 1. (A) IL-15 serum levels in patients with Parkinson’s disease treated with levodopa (group A), in untreated PD patients
(group B) and in healthy controls (group C). (B) RANTES serum levels in patients with PD treated with levodopa (group A), in
untreated PD patients (group B) and in healthy controls (group C).
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levodopa-treated PD patients were significantly
higher with respect to those from healthy controls
and higher, although not significantly, with respect to
those from untreated PD patients (Fig. 1A,B).
In previous papers, it has been demonstrated that
levodopa exerts an immuno-modulatory effect on
PBMC from PD patients, with an enhancement of IL-6
and TNF-a production by PBMC from PD patients.
1
Even if no correlation between IL-15 or RANTES
and stage or duration of disease among our patients
was found, the possibility that disease stage may
contribute to the enhanced expression of these
cytokines cannot be excluded.
So we hypothesize, in agreement with other
authors, that the immunological alterations observed
in levodopa-treated patients might be linked, both to
levodopa treatment and to disease progression.
Furthermore, the contemporaneous increase of
circulating IL-15 and RANTES among patients with
advanced stage of disease and severe functional
impairment may reflect the tight link between these
mediators.
In fact, an important action of IL-15 is the induction
of CC-type, CXC-type and C-type chemokines in T
lymphocytes and CC chemokine receptors, such as
RANTES and MIP-1a.
5
Normal human microglia expresses constitutively
mRNA transcripts for IL-15 and for IL-15R.
3 Activated
microglia in neurological diseases such as Alzheimer
disease, amyotrophic lateral sclerosis, stroke or PD
can overproduce mediators of phlogosis and activate
peripheral metabolic, endocrine and immune re-
sponses.
2
Our results on IL-15 and RANTES circulating levels
strengthen the data about the existence of a tight
connection between the central nervous system and
the immune system.
The increase of IL-15 production may enhance the
further recruitment of inflammatory cells in brain by
RANTES induction, so increasing the cerebral inflam-
mation.
In conclusion, this study may contribute to a better
definition of immunological network involved in PD.
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